Abstract: Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors that arise from neuroendocrine cells, and in some cases are capable of producing agents that may cause characteristic hormonal syndromes (Cives and Strosberg, 2018). Such tumors were previously thought to be rare, but the rate of detection of NENs, especially from the gastrointestinal tract, is increasing with the widespread use of colonoscopy, cross-sectional imaging, and biomarkers (Gu et al., 2019). A study based on the Surveillance, Epidemiology, and End Results (SEER) database showed that the age-adjusted incidence of NENs increased 6.4-fold from 1973 (1.09 per 100 000) to 2012 (6.98 per 100 000) (Dasari et al., 2017), while there was a progressive increase in the incidence of colorectal NENs (Starzyńska et al., 2017).

左右半结直肠神经内分泌肿瘤的生存差异研究

[1]Benson AB III, Venook AP, Cederquist L, et al., 2017. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15(3):370-398.

[2]Cesar D, Zanatto RM, da Silva MV, et al., 2013. Colon and rectum neuroendocrine tumors: experience of the National Cancer Institute in Brazil. Arq Bras Cir Dig, 26(1): 36-39.

[3]Cives M, Strosberg JR, 2018. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin, 68(6):471-487.

[4]Clark OH, Benson AB III, Berlin JD, et al., 2009. NCCN clinical practice guidelines in oncology: neuroendocrine tumors. J Natl Compr Canc Netw, 7(7):712-747.

[5]Dasari A, Shen C, Halperin D, et al., 2017. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol, 3(10):1335-1342.

[6]Garcia-Carbonero R, Sorbye H, Baudin E, et al., 2016. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology, 103(2):186-194.

[7]Gu Q, Lin YM, Cen L, et al., 2019. Endoscopic ultrasonography is useful in the diagnosis and treatment of rectal neuroendocrine neoplasms: a case series. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 20(10):861-864.

[8]Jernvall P, Mäkinen MJ, Karttunen TJ, et al., 1999. Microsatellite instability: impact on cancer progression in proximal and distal colorectal cancers. Eur J Cancer, 35(2): 197-201.

[9]Meguid RA, Slidell MB, Wolfgang CL, et al., 2008. Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol, 15(9):2388-2394.

[10]Mik M, Berut M, Dziki L, et al., 2017. Right- and left-sided colon cancer—clinical and pathological differences of the disease entity in one organ. Arch Med Sci, 13(1):157-162.

[11]Mitry E, Baudin E, Ducreux M, et al., 1999. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer, 81(8):1351-1355.

[12]Modlin IM, Lye KD, Kidd M, 2003. A 5-decade analysis of 13,715 carcinoid tumors. Cancer, 97(4):934-959.

[13]Patta A, Fakih M, 2011. First-line cisplatin plus etoposide in high-grade metastatic neuroendocrine tumors of colon and rectum (MCRC NET): review of 8 cases. Anticancer Res, 31(3):975-978.

[14]Popat S, Hubner R, Houlston RS, 2005. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol, 23(3):609-618.

[15]Portale TR, Branca A, Pesce A, et al., 2012. Neuroendocrine carcinoma of colon and rectum: a rare neoplasia with a poor prognosis. Minerva Chir, 67(3):283-284.

[16]Price TJ, Beeke C, Ullah S, et al., 2015. Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease? Cancer, 121(6):830-835.

[17]Sahnane N, Furlan D, Monti M, et al., 2015. Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity. Endocr Relat Cancer, 22(1): 35-45.

[18]Snaebjornsson P, Jonasson L, Jonsson T, et al., 2010. Colon cancer in Iceland—a nationwide comparative study on various pathology parameters with respect to right and left tumor location and patients age. Int J Cancer, 127(11): 2645-2653.

[19]Starzyńska T, Deptała A, Królicki L, et al., 2013. Colorectal neuroendocrine neoplasms—management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol, 64(6):494-504.

[20]Starzyńska T, Londzin-Olesik M, Bałdys-Waligórska A, et al., 2017. Colorectal neuroendocrine neoplasms—management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol, 68(2):250-260.

[21]Yao JC, Hassan MM, Phan A, et al., 2008. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol, 26(18):3063-3072

[22]List of electronic supplementary materials

[23]Table S1 Multivariable Cox regression of independent variables for cancer-specific risk of death